Myelodysplastic Syndrome
As part of our Haematology Horizons practice pearl series, Dr Douglas Tremblay (Icahn School of Medicine at Mount Sinai, New York City, NY, USA) shares his expert insights on how luspatercept and imetelstat are reshaping first- and second-line treatment strategies for lower-risk MDS. He shares practical insights on patient selection, sequencing therapy, managing cytopenias and where the greatest unmet needs remain in contemporary practice.
2025 has brought exciting developments in haematology, with groundbreaking research and real-world progress showcased at EHA, ASH, EBMT and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
The 67th ASH Annual Meeting and Exposition brought over 30,000+ attendees, 5,000+ novel abstracts and 275+ exhibitors corporate supporters, academic leaders and patient-advocacy groups. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of haematology practice.
A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
This September, for Blood Cancer Awareness Month (BCAM), the MDS Foundation proudly launched Voices of MDS — an awareness and storytelling campaign inviting the patient and caregiver community to share their MDS journeys.
The European Hematology Association (EHA) has released its official EHA Perspectives in Hematology reports from the 2025 Annual Congress in Milan, now available in two separate editions covering malignant and non-malignant hematology. Following strong interest in the 2024 pilot report, this expanded format offers deeper insights into scientific and clinical advances across the field.
As touchHAEMATOLOGY approaches 20 years of providing education for busy haematologists, we are looking to the future—and it certainly looks bright!
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and ...
The American Society of Hematology (ASH) held its 66th Annual Meeting from 7–10 December 2024. Among the highlights of the meeting were six late-breaking abstracts that have the potential to influence how healthcare professionals approach a range of condition,s from introducing ...
Prof. Pierre Fenaux, Head of the Department of Hematology and Immunology at Assistance Publique-Hôpitaux de Paris Nord (Hôpitaux Saint-Louis, R Debré, Avicenne) is a leading expert in haematology with extensive experience in the treatment and management of myelodysplastic syndromes (MDS). In this interview, he discusses key considerations for first-line therapies in lower-risk MDS, the latest advances in treatment and the role of organizations like the European School of Hematology (ESH) in supporting haematologists.
The phase 2 KER050-MD-201 trial investigates elritercept, an activin receptor ligand trap, for treating lower-risk myelodysplastic neoplasms (LR-MDS) with anaemia. The study, as of September 2023, involved 79 participants, evaluating safety, tolerability, and response to treatment. Most participants experienced mild-to-moderate adverse events, with dyspnea and diarrhoea being most common. Of those evaluated for at least 24 weeks (N=60), half achieved haematological improvement or transfusion independence, particularly those with lower erythropoietin levels. Responses were durable, with 72% maintaining independence beyond 24 weeks. Elritercept shows promise for addressing LR-MDS and improving quality of life. Further updates will provide long-term data
The EHA 2024 congress has once again united top haematology experts from around the globe. This year's event featured plenty of innovations and developments, from novel therapies to cutting-edge genetic studies. In this article we provide an overview of the late-breaking abstracts presented at the meeting.
The IMerge Phase 3 study (NCT02598661) is a phase 2/3 global study investigating imetelstat, a first-in-class telomerase inhibitor, for patients with red blood cell transfusion-dependent non-del(5q) lower risk-myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis-stimulating agents (ESAs). We were joined ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
